Kurser indlæses...

Prognose

Analytikernes gennemsnitlige kursmål er 4,99 € (-5,85 %). Medianen er 4,99 € (-5,85 %).

Køb	3
Behold	1
Sælg	1

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

Nyheder Til nyhedsfeedet

Cytek Biosciences loses part of lawsuit, ordered to pay $56 million in damages

A U.S. court ruled in a patent dispute against Cytek Biosciences that three of four patent claims were not infringed and are invalid, but found infringement under the doctrine of equivalents for the fourth claim. The court awarded $56 million in damages, including $20 million for lost profits and $36 million for royalties. Cytek said it will appeal the decision and the damages award, and emphasized that the judgment does not require any changes to its products or business operations. » Mere på de.investing.com
Cytek Biosciences reports 6% revenue growth but misses EPS expectations

Cytek Biosciences reported Q1 2026 revenue of $44.1 million (up 6% year‑over‑year) and saw strong growth of 32% in the U.S. Earnings per share were a loss of $0.15, missing the forecast of -$0.10; operating expenses rose 13% due to higher legal and administrative costs. The stock fell 6.68% in after‑hours trading. The company maintains revenue guidance of around $208 million for 2026 and $224.95 million for 2027 and emphasizes investments in products such as the Aurora Evo system. » Mere på de.investing.com
Cytek Biosciences presents growth strategy after moderate revenue increase in 2025

Cytek Biosciences reported revenue of USD 201.5 million for 2025, up 1% and thus outperforming the flow cytometry market (-4%). Recurring revenue rose to 34%; new products such as Aurora Evo and Muse Micro, expansion in APAC and a new manufacturing site in Singapore contributed to the growth. The cash position of USD 261.5 million provides room for acquisitions and share buybacks. For 2026, Cytek expects strong growth in the services and reagents segments and plans to expand its clinical business in Europe and China. » Mere på de.investing.com
Cytek Biosciences posts record revenue, misses profit target by a wide margin

Cytek Biosciences reported record revenue of $62.1 million (+8%) in the fourth quarter of 2025 with EPS of -$0.34, well below the expected -$0.02. Strong demand in EMEA and APAC and the expansion of product and bioinformatics offerings contributed to revenue growth, while higher operating costs and an impairment weighed on profitability. The stock rose 2.52% in after-hours trading; management forecasts continued revenue growth and plans to focus on higher‑margin product lines and expand bioinformatics and reagents. » Mere på de.investing.com
Cytek Biosciences unveils Aurora Evo and confirms full-year guidance of -2% to +2%

At the Morgan Stanley Global Healthcare Conference, Cytek Biosciences presented the new Aurora Evo instrument and plans regional manufacturing to strengthen its market presence. Sales of Full Spectrum Profiling instruments recently rose 3%, revenues from reagents and services each grew 18% in the second quarter, and Cytek Cloud has over 20,000 users. The company maintains a full-year forecast of -2% to +2% and reports EBITDA margins of around 7%; clinical approvals and partnerships are expected to further support growth. » Mere på de.investing.com

Historisk udbytte Udbytte

Alle nøgletal for udbytte Alle nøgletal

I 2022 har Cytek Biosciences allerede udloddet 0,16 € i udbytte. Den seneste udlodning fandt sted i marts 2022.

Virksomhedstal

I det seneste kvartal havde Cytek Biosciences en omsætning på 46,99 mio. € og et nettoresultat på -5,38 mio. €

(EUR)	september 2026	YoY
Omsætning	46,99 mio.	5,46 %
Bruttofortjeneste	27,55 mio.	17,35 %
Nettoresultat	-5,38 mio.	15,31 %
EBITDA	-5,87 mio.	63,41 %

Fundamentale data

Nøgletal	Værdi
Markedsværdi	686,97 mio. €
Antal aktier	130,78 mio.
Højeste/laveste i 52 uger	5,75 € - 3,00 €
Udbytte	Nej
Beta	1,14
P/E (PE Ratio)	-9,20
PEG (PEG Ratio)	0,03
K/I (PB Ratio)	2,35
P/S (PS Ratio)	3,65

Virksomhedsprofil

Cytek Biosciences, Inc., et selskab inden for celleanalyseløsninger, leverer værktøjer til celleanalyse, der fremmer videnskabelige fremskridt inden for biomedicinsk forskning og kliniske anvendelser. Selskabet tilbyder Aurora- og Northern Lights-systemer, som er spektrale flowcytometre, der udfører celleanalyse ved at udnytte fluorescenssignaturer fra flere lasere til at skelne fluorescerende markører på enkeltceller; og Aurora-cellesorteringssystemet, som anvender fuldspektret profileringsteknologi til yderligere at udvide de potentielle anvendelser inden for celleanalyse. Selskabet leverer også reagenser og kits, herunder cFluor-reagenser, som er fluorokrom-konjugerede antistoffer, der bruges til at identificere celler af interesse til analyse på dets instrumenter, samt et 25-farvet immunprofileringsassay, der leverer turnkey-løsninger til identifikation af store humane immunundergrupper for TBNK-celler, monocytter, dendritceller og basofile celler. Derudover tilbyder det et automatiseret mikroprøvetagningssystem og et automatiseret prøveindlæsningssystem, som er automatiserede pladeindlæsere, der integreres problemfrit i Aurora- og Northern Lights-systemerne; SpectroFlo-software, der giver en intuitiv arbejdsgang fra kvalitetskontrol til dataanalyse for Aurora- og Northern Lights-systemerne; og kundesupportværktøjer. Selskabet betjener farmaceutiske og biofarmaceutiske virksomheder, akademiske forskningscentre og kliniske forskningsorganisationer. Det distribuerer sine produkter gennem egen salgsstyrke og supportorganisationer i Nordamerika, Europa, Kina og Asien-Stillehavsregionen; og gennem distributører eller salgsagenter i europæiske, latinamerikanske, mellemøstlige og asiatisk-stillehavslande. Selskabet var tidligere kendt som Cytoville, Inc. og ændrede navn til Cytek Biosciences, Inc. i august 2015. Cytek Biosciences, Inc. blev grundlagt i 1992 og har hovedkvarter i Fremont, Californien.

Navn	Cytek Biosciences
CEO	Wenbin Jiang
Hjemsted	Fremont, ca USA
Websted	cytekbio.com
Sektor	Sundhed
Branche	Sundhedsudstyr og -produkter
Børsnotering	23.07.2021
Medarbejdere	700